Table 3 Factors associated with impacted/improved overall survival and progression-free survival.
Overall survival | Progression-free survival | |||||
|---|---|---|---|---|---|---|
Factors | n | HR (95% CI) | P | n | HR (95% CI) | P |
Demographics | ||||||
Age (years) < 60 vs. ≥ 60 | 70 | 1.1 (0.6–2.1) | 0.768 | 70 | 1.2 (0.7–2.1) | 0.589 |
Sex male vs. female | 70 | 1.3 (0.7–2.7) | 0.434 | 70 | 1.2 (0.6–2.3) | 0.623 |
Karnofsky index ≤90% vs. >90% | 70 | 1.4 (0.7–2.8) | 0.363 | 70 | 1.3 (0.7–2.4) | 0.437 |
Diagnosis before alloHCT | ||||||
Diagnosis of MCL ± AHN yes vs. no | 70 | 2.0 (0.9–4.4) | 0.088 | 70 | 3.5 (1.7–7.5) | <0.001 |
Diagnosis of AML yes vs. no | 70 | 1.4 (0.7–2.7) | 0.309 | 70 | 1.3 (0.7–2.3) | 0.401 |
Cytogenetics | ||||||
Aberran yes vs. no | 60 | 1.6 (0.8–3.3) | 0.188 | 60 | 1.6 (0.8–3.1) | 0.156 |
Complex aberrant yes vs. no | 60 | 4.2 (1.8–10.0) | 0.001 | 60 | 3.0 (1.4–6.6) | 0.006 |
Mutations | ||||||
Absence of KIT D816V yes vs. no (or unknown) | 61 | 2.8 (1.2–6.5) | 0.016 | 61 | 2.5 (1.2–5.4) | 0.021 |
Presence of S/A/R yes vs. no | 47 | 0.8 (0.4–1.7) | 0.599 | 56 | 0.6 (0.3–1.2) | 0.146 |
≥3 additional somatic mutations yes vs. no | 56 | 1.3 (0.6–2.8) | 0.432 | 56 | 1.0 (0.5–2.1) | 0.904 |
Treatment before alloHCT | ||||||
With tyrosine kinase inhibitors yes vs. no | 70 | 0.6 (0.3–1.1) | 0.091 | 70 | 0.5 (0.2–0.9) | 0.014 |
Response status before alloHCTa | ||||||
For SM yes vs. no | 41 | 0.4 (0.2–0.9) | 0.035 | 41 | 0.6 (0.3–1.2) | 0.143 |
For AHN including AML yes vs. no | 43 | 0.3 (0.1–0.7) | 0.004 | 43 | 0.5 (0.2–1.0) | 0.067 |
Time to alloHCT | ||||||
From SM (years) ≥1 vs. <1 | 70 | 1.0 (0.5–1.9) | 0.946 | 70 | 0.8 (0.4–1.4) | 0.377 |
From AHN (years) ≥1 vs. <1 | 70 | 1.5 (0.7–3.0) | 0.297 | 70 | 1.4 (0.7–2.6) | 0.332 |
Biomarkers at alloHCT | ||||||
Tryptase (µg/L) ≥100 vs. <100 | 50 | 0.9 (0.4–1.9) | 0.748 | 50 | 1.0 (0.5–2.1) | 0.928 |
Mast cell infiltration (%) ≥25 vs. <25 | 53 | 1.3 (0.6–2.7) | 0.468 | 53 | 1.7 (9.9–3.4) | 0.123 |
Transplantation | ||||||
Conditioning Reduced intensity vs. myeloablative | 69 | 0.9 (0.5–1.8) | 0.871 | 69 | 0.9 (0.5–1.7) | 0.802 |
Total body irradiation ≥ 8 Gy yes vs. no | 17 | 0.9 (0.2–3.1) | 0.807 | 17 | 0.7 (0.2–2.1) | 0.480 |
HLA match 10/10 vs. others | 62 | 1.2 (0.6–2.5) | 0.571 | 62 | 1.2 (0.6–2.4) | 0.527 |
alloHCT before 2009 yes vs. no | 70 | 1.1 (0.4–3.1) | 0.799 | 70 | 1.3 (0.5–3.5) | 0.545 |
alloHCT at a center with above-average numbers of alloHCT in AdvSM b yes vs. no | 70 | 1.0 (0.5–2.0) | 0.964 | 70 | 1.1 (0.6–2.0) | 0.802 |
Full donor chimerism (≥95% donor signal within 30 days) yes vs. no | 43 | 0.5 (0.1–1.9) | 0.136 | 43 | 0.2 (0.1–1.6) | 0.051 |
